The Bigger the Ship, the Harder It Is to Turn: Continued Clinical Inertia With SGLT2i Utilization in Heart Failure

被引：0
|
作者：
Lyle, Melissa [1 ]
Santos-Gallego, Carlos G. [2 ]
机构：
[1] Mayo Clin, Div Adv Heart Failure & Transplant Cardiol, Jacksonville, FL 32224 USA
[2] Icahn Sch Med Mt Sinai, Cardiovasc Inst, Athero Thrombosis Res Unit, New York, NY USA
来源：
JOURNAL OF CARDIAC FAILURE | 2024年 / 30卷 / 09期
关键词：
EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1016/j.cardfail.2024.05.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1098 / 1099
页数：2
相关论文
共 41 条
  • [1] Growing role of SGLT2i in heart failure: evidence from clinical trials
    Varadhan, Ajay
    Stephan, Katarina
    Gupta, Rahul
    Vyas, Apurva V.
    Ranchal, Purva
    Aronow, Wilbert S.
    Hawwa, Nael
    Lanier, Gregg M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (02) : 147 - 159
  • [2] Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes
    Jose Rodriguez, Juan
    Ortega-Paz, Luis
    Brugaletta, Salvatore
    Sabate, Manel
    AIMS MEDICAL SCIENCE, 2018, 5 (01): : 67 - 79
  • [3] Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
    Correale, Michele
    Lamacchia, Olga
    Ciccarelli, Michele
    Dattilo, Giuseppe
    Tricarico, Lucia
    Brunetti, Natale Daniele
    HEART FAILURE REVIEWS, 2023, 28 (03) : 733 - 744
  • [4] Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis
    Younes, Ahmed M.
    Salem, Mahmoud
    Maraey, Ahmed
    Nomigolzar, Soroush
    Sewell, Kerry
    Khalil, Mahmoud
    Elzanaty, Ahmed
    Saeyeldin, Ayman
    Dar, Moahad
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 366 : 51 - 56
  • [5] SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
    Requena-Ibanez, Juan Antonio
    Santos-Gallego, Carlos G.
    Badimon, Juan Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2022, 75 (10): : 833 - 841
  • [6] Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
    Milder, Tamara Y.
    Lin, Jialing
    Pearson, Sallie-Anne
    Costa, Juliana de Oliveira
    Neuen, Brendon L.
    Pollock, Carol
    Jun, Min
    Greenfield, Jerry R.
    Day, Richard O.
    Stocker, Sophie L.
    Brieger, David
    Falster, Michael O.
    DIABETES OBESITY & METABOLISM, 2025, 27 (02) : 997 - 1000
  • [7] SGLT2 inhibitors and heart failure - clinical implications
    Raz, Itamar
    Cahn, Avivit
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (04) : 185 - 186
  • [8] Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF
    Bocchi, Edimar Alcides
    Biolo, Andrea
    Moura, Lidia Zytynski
    Figueiredo Neto, Jose Albuquerque
    Lucena Montenegro, Carlos Eduardo
    de Albuquerque, Denilson Campos
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 116 (02)
  • [9] SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis
    Yan, Yuling
    Liu, Bin
    Du, Jun
    Wang, Jing
    Jing, Xiaodong
    Liu, Yajie
    Deng, Songbai
    Du, Jianlin
    She, Qiang
    ESC HEART FAILURE, 2021, 8 (03): : 2210 - 2219
  • [10] Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy
    Kittipibul, Veraprapas
    Vaduganathan, Muthiah
    Ikeaba, Uchechukwu
    Chiswell, Karen
    Butler, Javed
    Devore, Adam D.
    Heidenreich, Paul A.
    Huang, Joanna C.
    Kittleson, Michelle M.
    Maddox, Karen E. Joynt
    Linganathan, Karthik K.
    Mcdermott, James J.
    Owens, Anjali Tiku
    Peterson, Pamela N.
    Solomon, Scott D.
    Vardeny, Orly
    Yancy, Clyde W.
    Fonarow, Gregg C.
    Greene, Stephen J.
    JACC-HEART FAILURE, 2024, 12 (08) : 1409 - 1421
12345